Key result
Adjuvant chemotherapy with doxorubicin did not significantly increase the proportion of women with LVEF <50% at 5 to 8 years compared to non-doxorubicin regimens (5% vs 7%; P=0.68).
Why the study?
Does adjuvant chemotherapy with doxorubicin increase the likelihood of late adverse cardiac effects (LVEF <50%) in breast cancer survivors compared to chemotherapy without doxorubicin?
Cohort (n=180)
Yes
Does adjuvant chemotherapy with doxorubicin increase the likelihood of late adverse cardiac effects (LVEF <50%) in breast cancer survivors compared to chemotherapy without doxorubicin?
Absolute Event Rate: 5% vs 7%
p-value: p=.68
In a selected sample of breast cancer survivors with up to 13 years of follow-up, exposure to doxorubicin did not significantly increase the likelihood of late adverse cardiac effects such as LVEF <50%.
No takes yet. Share an insight, caveat, or question.
Doxorubicin exposure was not associated with higher late LVEF <50% rates in this cohort; leaves open need for larger prospective studies in broader survivors.
Ganz et al. (2008) conducted a cohort in Early-stage breast cancer (n=180). Adjuvant chemotherapy with doxorubicin (CAF) vs. Adjuvant chemotherapy without doxorubicin (CMF) was evaluated on LVEF less than 50% at 5 to 8 years (p=.68). Adjuvant chemotherapy with doxorubicin did not significantly increase the proportion of women with LVEF <50% at 5 to 8 years compared to non-doxorubicin regimens (5% vs 7%; P=0.68).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: